Surufatinib plus immunotherapy and chemotherapy for bile duct cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of drugs for people with bile duct cancer that cannot be removed by surgery or has spread. The treatment combines a targeted drug (surufatinib) with immunotherapy and chemotherapy to try to shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have bile duct cancer that has spread or cannot be removed with surgery.
- You are 18 or older.
- You are well enough to carry out daily activities (ECOG score 0-1).
- Your liver function is adequate (Child-Pugh A or B).
- You have at least one measurable tumor by scans (per RECIST).
- Your blood counts, liver, kidney, and heart functions are within acceptable limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two chemotherapy drugs and an immunotherapy drug, followed by targeted radiation, in people with bile duct or gallbladder cancer that cannot be removed with surgery. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a combination of a targeted therapy (surufatinib), chemotherapy (gemcitabine and cisplatin), and an immunotherapy (durvalumab or pembrolizumab) for people with advanced bile duct cancer that hasn't been treated with systemic therapy before. The goal is to see if this combination can shrink tumors and improve outcomes.
This study tests a combination of two drugs (surufatinib and toripalimab) plus a chemo infusion directly into the liver (HAIC) for people with bile duct cancer that cannot be removed by surgery or has spread. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a combination of two medications (envafolimab and surufatinib) plus a procedure that uses heat to destroy cancer cells inside the bile ducts. It is for people with bile duct or gallbladder cancer that cannot be removed surgically and who are not candidates for or do not want chemotherapy.
This trial tests a combination of three drugs for a rare type of cancer at the ampulla of Vater, where the bile duct and pancreatic duct meet. The goal is to see if this combination can shrink tumors or slow their growth in people whose cancer cannot be removed with surgery or has come back.
This trial studies whether a combination of surufatinib and immunotherapy (camrelizumab, plus an “AS” medicine) can slow or shrink advanced pancreatic cancer that has spread. It is for people starting treatment for advanced disease for the first time and may help those who have measurable tumors and meet safety test limits.
Hear when a new Biliary Tract Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.